Search anything and hit enter
  • Teams
  • Members
  • Projects
  • Events
  • Calls
  • Jobs
  • publications
  • Software
  • Tools
  • Network
  • Equipment

A little guide for advanced search:

  • Tip 1. You can use quotes "" to search for an exact expression.
    Example: "cell division"
  • Tip 2. You can use + symbol to restrict results containing all words.
    Example: +cell +stem
  • Tip 3. You can use + and - symbols to force inclusion or exclusion of specific words.
    Example: +cell -stem
e.g. searching for members in projects tagged cancer
Search for
Count
IN
OUT
Content 1
  • member
  • team
  • department
  • center
  • program_project
  • nrc
  • whocc
  • project
  • software
  • tool
  • patent
  • Administrative Staff
  • Assistant Professor
  • Associate Professor
  • Clinical Research Assistant
  • Full Professor
  • Graduate Student
  • Lab assistant
  • Non-permanent Researcher
  • Permanent Researcher
  • Pharmacist
  • PhD Student
  • Physician
  • Post-doc
  • Project Manager
  • Research Associate
  • Research Engineer
  • Retired scientist
  • Technician
  • Undergraduate Student
  • Veterinary
  • Visiting Scientist
  • Deputy Director of Center
  • Deputy Director of Department
  • Deputy Director of National Reference Center
  • Deputy Head of Facility
  • Director of Center
  • Director of Department
  • Director of Institute
  • Director of National Reference Center
  • Group Leader
  • Head of Facility
  • Head of Operations
  • Head of Structure
  • Honorary President of the Departement
  • Labex Coordinator
Content 2
  • member
  • team
  • department
  • center
  • program_project
  • nrc
  • whocc
  • project
  • software
  • tool
  • patent
  • Administrative Staff
  • Assistant Professor
  • Associate Professor
  • Clinical Research Assistant
  • Full Professor
  • Graduate Student
  • Lab assistant
  • Non-permanent Researcher
  • Permanent Researcher
  • Pharmacist
  • PhD Student
  • Physician
  • Post-doc
  • Project Manager
  • Research Associate
  • Research Engineer
  • Retired scientist
  • Technician
  • Undergraduate Student
  • Veterinary
  • Visiting Scientist
  • Deputy Director of Center
  • Deputy Director of Department
  • Deputy Director of National Reference Center
  • Deputy Head of Facility
  • Director of Center
  • Director of Department
  • Director of Institute
  • Director of National Reference Center
  • Group Leader
  • Head of Facility
  • Head of Operations
  • Head of Structure
  • Honorary President of the Departement
  • Labex Coordinator
Search
Go back
Scroll to top
Share

About

Our work mainly focuses on cellular and molecular aspects

of the replication of HIV and SARS-CoV-2,

and on the interplay between viruses and the host.

We are investigating how pathogenic viruses, mainly HIV, Zika virus and SARS-CoV-2 virus, spread and interact with the host immune system. We are also studying the mechanisms of cell fusion that is either induced by viral infection, or naturally occurs during physiological processes such as placental formation.

Our scientific activities are characterized by three close and complementary axes of research. We are currently studying:

 

dessin1_bis.jpg dessin2_bis.jpg
An artistic view of cells and viruses drawings by Fabrice HYBER
When scientists meet artists: http://www.organoide-pasteur.fr

 

Virus and Immunity Unit

March 20, 2020 (lab meeting at the beginning of the lockdown)

June 2019 Lab meeting with Alumni


March 2018

October 2016

equipe-pasteur-copie-jpg


October 2014

photo du labo

 

First Axis
Mechanisms of HIV-1 replication and interaction with the immune system

About 40 years after its appearance, the HIV/AIDS epidemic represents more than ever a public health threat worldwide. As of 2018, approximately 38 million people are living with HIV/AIDS, with most of them originating from developing countries. Our work focuses on the cellular and molecular aspects of HIV-1 replication, and on the mechanisms of interaction between HIV-infected cells and the immune system. We are currently pursuing three complementary axes of research on this subject:

We are studying viral cell-to-cell spread. Direct cell-to-cell transfer represents a potent and rapid mode of viral propagation, which involves the formation of virological synapses between infected donor cells and uninfected recipients. We are examining the role of cellular and viral proteins which facilitate viral spread. We are deciphering the underlying mechanisms.

HIV cell-to-cell transfer in lymphocytes (HIV in green, target cell in blue)

HIV budding at the contact zone between one infected and one target cell

We are also studying the role of the viral protein Nef, which facilitates viral replication by interfering with the antiviral activity of cellular proteins (SERINC proteins), and which also modulates the trafficking of proteins, such as MHC-I that are involved in immune responses.

 

MHC-I intracellular localization in non-infected (right) and Nef-expressing lymphocytes

We are also examining how cellular proteins may inhibit viral spread. These proteins are called restriction factors and are often induced by type-I Interferons. We are studying for instance the role of IFITMs (Interferon induced Transmembrane proteins), which impair viral fusion and then access of incoming virions to the cytoplasm. Our aim is to understand how IFITM proteins inhibit HIV-1 replication and how the virus counteracts this effect.

 

Movie: Real time imaging of HIV-1 cell-to-cell transmission (from https://www.ncbi.nlm.nih.gov/pubmed/19369333).

Strategies to eliminate the HIV-1 reservoir

In collaboration with the teams of Hugo Mouquet (Institut Pasteur), and Olivier Lambotte (Bicêtre Hospital), we have demonstrated that bNAbs act in complementary ways. Firstly, they neutralize both cell-free virions and direct cell to cell viral spread. Secondly, the most potent bNAbs bind infected cells and trigger so called effector functions mediate by the Fc domain of the antibody.

We have shown that some bNAbs trigger the destruction of infected cells by Natural Killer (NK) cells through a process termed antibody-dependent cellular cytotoxicity (ADCC). We are currently studying how bNAbs activate the complement pathway at the surface of infected cells.

The complement is a network of proteins initially described for its ability to induce cell toxicity. Due to its ancestral origin, the complement is highly intricated within innate and adaptive immune systems. Complement deposition at the plasma membrane triggers intrinsic signaling pathways impacting cell fate or activation.

Our current aims are to study the mechanisms of ADCC and complement deposition by bNAbs and to further assess the ability of bNAbs to clear the HIV-1 reservoir, in cells from patients under successful antiretroviral treatment.

Overall, this project should provide new insights into the activity of antibodies during HIV-1 infection. More generally, it will also help define the mechanisms of antibody-based therapeutic strategies.

Example of HIV-1-infected cell killing by NK cells: An HIV-1 infected cell (green) and NK (smaller dark cells) are incubated with a bNAb and trapped in a microwells. A picture is taken every 5 minutes. A blue dye reveals the dying cell (Bruel et al. 2016)

 

Second Axis
The biology and physiopathology of SARS-CoV-2 infection

The ongoing COVID-19 pandemic poses a significant global public health threat and will require an unprecedented research effort in order to provide novel therapeutic and vaccinal strategies. Gaining an understanding of SARS-CoV-2 multiplication and its physiopathology is of the utmost importance.

The innate and adaptative immune response controls viral spread and disease development in most of infected individuals, through mechanisms that are not clearly understood. Severe cases of COVID-19 are associated with extensive lung damage and the presence of infected multinucleated syncytial pneumocytes. The viral and cellular mechanisms regulating the formation of these syncytia are not well understood. We have observed that SARS-CoV-2 infected cells express the Spike protein (S) at their surface and fuse with ACE2-positive neighboring cells (see video below). Expression of S without any other viral proteins triggers syncytia formation. Interferon-induced transmembrane proteins (IFITMs), inhibit S-mediated fusion, with IFITM1 being more active than IFITM2 and IFITM3. On the contrary, the TMPRSS2 serine protease, which is known to enhance infectivity of cell-free virions, processes both S and ACE2 and increases syncytia formation by accelerating the fusion process. TMPRSS2 thwarts the antiviral effect of IFITMs. Our results show that SARS-CoV-2 pathological effects are modulated by cellular proteins that either inhibit or facilitate syncytia formation. We are currently examining the mechanisms underlying SARS-CoV-2 replication and cell fusion. We are studying the cytopathic effect of the virus, that is to say the morphological changes in infected cells, in order to understand what happens during the later stages of the viral life cycle. Our aim is to understand how SARS-CoV-2 replicates despite this cytopathic effect, and to further describe the protective innate response of the host. We are using video microscopy, immunofluorescence, electron microscopy and other techniques to address these questions.

SARS-CoV-2 infected cells fusing with neighboring cells. Red: SARS-CoV-2 Spike protein, Green: Fused cells, Blue: nuclei. (see Buchrieser et al, 2020 for more details)


« Human bronchial cells infected by SARS-CoV-2. Scanning electron microscopy. Cells are pseudocolored in blue and virus in orange » (c) Institut Pasteur. Image par Rémy Robinot, Mathieu Hubert, Vincent Michel, Olivier Schwartz & Lisa Chakrabarti, colors by Jean Marc Panaud

Analysis of anti-SARS-CoV-2 antibody function

We have established two cell-based assays to detect, quantify the levels and analyze the neutralizing activity of anti-SARS-CoV-2 antibodies in infected individuals. The first assay is a flow-cytometry based assay (termed S-Flow) which measures the amounts of anti-Spike protein in serum samples. The second assay (termed S-Fuse), allows the rapid measurement of neutralizing antibodies. With these assays, we are studying the humoral response and its duration in different categories of infected individuals. We are also assessing the effector function (ADCC, Complement deposition…) of these antibodies

Our recent articles and preprints on SARS-CoV-2 and COVID-19 (see the publication list section, for full reference and link to the articles):
1. J. Buchrieser et al. Syncytia formation by SARS-CoV-2 infected cells. Biorxiv, 2020.2007.2014.202028 (2020).
2. S. Fafi-Kremer et al. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. EBioMedicine, 102915 (2020).
3. A. Fontanet et al. Cluster of COVID-19 in northern France: A retrospective closed cohort study. medRxiv, 2020.2004.2018.20071134 (2020).
4. D. E. Gordon, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, (2020).
5. L. Grzelak et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med, (2020).

 

Third Axis
Cell fusion during placenta formation

High-risk pregnancies occur frequently and may be caused by various factors. It is estimated that 10 to 20% of pregnant women miscarry during their first trimester of pregnancy, and 10% will experience pre-term birth. Slow fetal growth may also arise as a result of maternal infection with certain microbes, parasites or viruses (such as toxoplasmosis or infection with rubella virus, cytomegalovirus, herpes or Zika) or because of genetic or autoimmune diseases. We have identified a new cellular mechanism that alters placental development, potentially causing serious complications during pregnancy. The mechanism is linked with interferon, a molecule produced in response to infection, especially viral infection. The placenta is both a surface for exchange and a barrier between mother and fetus – it delivers nutrients needed for fetal growth, produces hormones and protects the fetus from microbes and the maternal immune system. The external layer of the placenta, the syncytiotrophoblast is composed of cells which fuse together, forming giant cells that are optimized for the placenta’s barrier and exchange functions. If the syncytiotrophoblast fails to form correctly, it can cause placental insufficiency and hinder fetal development.
Interferon is a substance produced by immune cells during infection to combat viruses and other intracellular microbes. High levels of interferon are also observed in autoimmune or inflammatory diseases such as lupus. Exaggerated levels of interferon are responsible for placental abnormality. We demonstrated that interferon induces the production of a family of cellular proteins known as IFITMs (interferon-induced transmembrane proteins), which block cell fusion. Our aim is to understand the mechanism of formation of the placenta under normal or pathological conditions, the mechanism of action of IFN and IFITM, and to study means to prevent placental defects.

 

Human cells fusing and forming syncytia (green area) when the Syncytin protein is expressed (left). This process is inhibited by IFITM2 (right). (Buchrieser et al, 2019)

 

Webmasters : Isma Ziani & Estelle Chaillat

SELECTED COVER PAGES

 

 

Former Members

2000
2000
Name
Position
2015
2020
Nathalie Sol-Foulon
2015
2020
Arnaud Moris
2015
2020
Samantha Brandler
2015
2020
Cinzia Nobile
2015
2020
Marion Sourisseau
2015
2020
Dominika Rudnicka
2015
2020
Daniela Vendrame
2015
2020
Stéphanie Louis
2015
2020
Fabrizio Mammano
2015
2020
Alice Lepelley
2015
2020
Eva-Maria Weiss
2015
2020
Jérôme Feldmann
2015
2020
Linda Obiang
2015
2020
Jean-Jacques Mention
2015
2020
Ferdinand Roesch
2015
2020
Isabel Puigdomenech
2015
2020
Anne Billet
PhD Student
2015
2020
Virginie Perrin
Research Engineer
2015
2020
Lise Chauveau
PhD Student
2015
2020
Norbert Couespel
PhD Student
2015
2020
Louise Veron
PhD Student
2015
2020
Talya Raphael
PhD Student
2015
2020
Nicolas Roy
Post-doc
2015
2020
Alex Compton
Post-doc
2015
2020
Sonia Amraoui
Post-doc
2015
2020
Guillaume Mestrallet
Undergraduate Student
2015
2020
Daniel Donahue
Post-doc
2015
2020
Cécile Meunier
Post-doc
2015
2020
Samy Sid Ahmed
PhD Student
2015
2020
Quentin Nevers
Post-doc
Show all

Projects

Transversal Project

Fundings

Publications

Download

Contact

Phone: +33 1 45 68 83 53 Email: olivier.schwartz@pasteur.fr Address Bât Lwoff 25-28 Rue du Docteur Roux 75015, Paris France